Participate in Research

Participate in Research

Before participating in any research study requiring you to change or add to your current antiseizure medication regime, please consult your neurologist or treating doctor to assess the individual risks of possible medication interactions or exacerbation of seizure activity.

Find Epilepsy Clinical Trials with HealthMatch

HealthMatch is an Australian health technology company designed to help patients directly access clinical trials. Epilepsy Action Australia has partnered with HealthMatch to provide members with easy access to the latest clinical trials being conducted throughout Australia.

You can sign up, select your condition, create a profile and answer a simple questionnaire to determine if you are eligible for any currently recruiting clinical trials. The platform allows users to create a profile which means that when new trials become available, you will automatically be notified of these opportunities.

HealthMatch can be used by members, their families and health professionals. To access HealthMatch please click on the banner below.

Types of Research

Epilepsy Research

Medicinal Cannabis

Epilepsy Research

Making Everyday Memory Optimal

Feel like you need help with your memory?  You’re not alone. Many people with acquired brain injuries notice memory difficulties.


We are developing a computer-based training program aimed at helping people like you, and we could use your input. If you are an adult (over the age of 18) with an acquired brain injury and have concerns about your memory, you might be eligible to try out this new program for free.

What’s involved: attending one-hour, group-based teleconferencing (Zoom) sessions (one per week, for six weeks) with an expert clinician; viewing short educational videos (and trying out some quiz questions); practicing computer-based exercises; receiving feedback.  Throughout this process, we will be collecting information on how the program works and asking for your opinions.

If you’d like to get involved, contact us via email [email protected] and we will be in touch.

The SELECT study – Consumer Advisory Board: recruiting for their consumer advisory board

Is looking to establish a consumer advisory board to join the team working on a clinical trial investigating sodium selenate as a treatment for medication resistant epilepsy (the SELECT study). The ideal person will have personal experience with medication resistant epilepsy, either as person with epilepsy or as a carer or family member of a person with epilepsy.
This is a randomised controlled trial and the main purpose is to look at whether the trial drug, sodium selenate, when given at 15mg three times a day for 26 weeks stops or reduces seizures, and whether this drug is disease-modifying, meaning the change in seizure frequency continues in the weeks and months after the drug is stopped.
The main outcome will look at: changes in seizure frequency, drug side effects, impact on mood and impact on thinking over 52 weeks. Up to 124 patients with drug resistant epilepsy will be recruited into the study from sites in Melbourne, Adelaide, Sydney, Perth and Brisbane over 2½ years with recruitment anticipated to start in late 2023.
There are two roles of the consumer advisors, you may choose to be involved in one or both:
1. Protocol development: Determining the priority of the study outcomes, that is, changes in seizure frequency, side effects, mood and thinking changes; making suggestions on the study protocol with respect to feasibility and/or additional measures which could be incorporated. This involves a discussion panel with the Project Manager & other people with epilepsy. This will take approx. 60-90 minutes & will take place both in person (Melbourne) & via zoom about March 2023.
2. Study advisory board: Providing consumer perspectives on study documents (such as consent forms and other patient facing material) and the ongoing conduct of the trial. This will involve reviewing of study documents sent via email with a follow up discussion with the Project Manager (via phone/zoom). Meetings will occur twice per year to update the advisory board on the study progress. Members of the advisory board will be invited to the annual investigator meeting (in person/via zoom) to be held in about February/March each year. The advisory board will consist of approx. 5 consumers.
If you are interested please contact the Project Manager, Lucy Vivash [email protected], or complete the Expression of Interest here…/1FAIpQLSdHdDpLDHL…/viewform…


Help design a seizure prediction device!

We are designing an EEG monitoring device for seizure prediction and would like your help to understand users’ needs and requirements!


If you have epilepsy or are a family member or a caregiver of someone with epilepsy, we are interested to hear your opinions.

As a participant, you will be asked to complete a short online survey and take part in an interview via Zoom. The study takes 40 minutes to complete. This study is conducted by a research team at the School of Computer Science.

To participate, please contact Adele Tong on [email protected]

Understanding Personalisation Needs of Wearable EEG Sensors through Online Semi-structured Interviews. Version 2.0 – 24/03/22


Macquarie University researchers are currently conducting a brief survey to understand the experience of symptom invalidation (i.e., the dismissal or rejection of health symptoms by doctors, family or friends) on Australian adults living with chronic physical health conditions. If you are interested in finding out more about this survey, click:








Epilepsy Risks and COVID-19 – Survey for people with epilepsy

SA Logo

The COVID-19 pandemic is impacting us all – and can be challenging for people with health conditions like epilepsy.

SUDEP Action & a research team at the University of Oxford, have designed a survey to understand your experience of living with and managing different aspects of epilepsy during the current COVID-19 pandemic. This survey can be done in a few minutes by anyone living with epilepsy, or their main caregiver, including parents, guardians or support workers (UK or International).

By participating, you can play a vital part in our COVID-19 Epilepsy risks project,  to help better understand the challenges people with epilepsy are facing, both due to the COVID-19 pandemic and more generally; so we can take action to help people stay safe and live well with epilepsy during the pandemic and beyond.

People with epilepsy – Complete the survey here

Caregivers of someone with epilepsy – Complete the survey here

Online Survey: currently recruiting


In this project, we want to find out more are about the well-being of teens and young adults with chronic physical conditions. You will be asked to complete an online survey which contains a number of questions about how you think and feel. Once you have completed the survey, you will receive a $10 voucher to either JBHifi or Big W (your choice).

This study is open to Australian residents, aged 16-25 years, who have been diagnosed with a chronic physical illness.

If you meet the above criteria and want to take part in this study, please click here!

Online Survey: currently recruiting

Quality of life in children with a genetically caused epilepsy disorder: currently recruiting

Researchers at the Telethon Kids Institute would like to talk with parents of children with a genetically caused epilepsy disorder. We wish to find out what challenges or helps quality of life. Findings will help researchers better determine how the lives of these children and their families can be improved.

Participants will be interviewed and it will take approximately one hour over the phone or online.

Who can take part?

Any parent of a child aged 2-18 years with a genetically caused epilepsy disorder

Contact for more information

Associate Professor Jenny Downs [email protected] phone (08) 6319 1763

Approved by Curtin University Human Research Ethics Committee (HREC) HRE2020-0687


Examining the efficacy of an online Cognitive Behaviour Therapy (CBT) – based self-management program for adults with neurological disorders


Macquarie University’s eCentreClinic is looking for adults with epilepsy to take part in a free online course to help Australians with neurological conditions learn to manage:

  • Stress, anxiety, frustration and worry.
  • Low mood, sadness, grief and depression.
  • Day-to-day mental or cognitive activities.
  • Day-to-day physical activities.

Click here to find out more about this Wellbeing Neuro Course and current research trial

Medicinal Cannabis

Join the QUEST: currently recruiting

Conducted by researchers at the University of Sydney, the QUality of life Evaluation STudy (QUEST Initiative) will be investigating the quality of life and health economic impact of prescribed medicinal cannabis on Australians with chronic disease over 12 months. The study is open to Australians with a range of conditions including chronic pain, cancer pain, neuropathic pain, insomnia, anxiety, multiple sclerosis and epilepsy.

You cannot participate if you are currently receiving medicinal cannabis treatment.

To learn more about the study, go to:

To find out if you are eligible, Click Here

Recruitment ends 31st March 2022

Study on Medicinal Cannabis is investigating epilepsy: recruiting closed

Around 30% of people with epilepsy can’t achieve seizure control using conventional medications. Cannabidiol (CBD), a therapeutic and non-intoxicating constituent of cannabis, has recently been approved as an add-on therapy for the management of some treatment-resistant epilepsy disorders. Evidence suggests that medicinal cannabis can improve seizure management and may improve other quality-of life symptoms associated with epilepsy. However, more research is needed and studies are being conducted.

The results from this study will be used to help improve accessibility.

Visit the website for more information: Clinical Research – Bod Pharmaceuticals

Cannabinoid Medicine Observational Study (CMOS): currently recruiting

Applied Cannabis Research (ACR), is commencing Australia’s largest observational study ever undertaken for medical cannabis. ACR will lead the study in conjunction with Australia’s medical community and key industry partners.

Working with clinical collaborators from major clinics and hospitals, the Cannabinoid Medicine Observational Study (CMOS)  will collect data from 20,000 patients nationwide to assess the safety and efficacy of medicinal cannabis products for a range of conditions including fibromyalgia, chronic pain syndromes, epilepsy and other neurological conditions, PTSD and other mental illness.

CMOS provides an opportunity to capture data from a broader range of Australian prescribers and patients than in existing studies. Australia’s Therapeutic Goods Administration (TGA) has now approved over 67,000 applications for medical cannabis. With a lack of randomised clinical trials within the space, there is an urgent need for large-scale evidence-based studies of prescribing medicinal cannabis. Feedback on treatment-related progress, dosing and side-effects is becoming increasingly relevant.

Key Highlights:

  • Some subsidised medicinal cannabis products may be available for study participants
  • Data is collected through progress-related questionnaires over a 12-month period, capturing data on efficacy, side effects, dosage, adherence to medication, changes to other concomitant medications and progressing health status
  • Patients may be asked to complete separate surveys according to relevant indications to monitor conditions such as pain, anxiety, depression, fatigue, sleep disorders, and physical function
  • Data is collected from both treating doctors and their patients to provide a complete view of their medical cannabis treatment journey
  • Data collected will be periodically fed back to participating doctors to inform patient care and for teaching
  • Patients are only identified by a unique study ID number

The CMOS study is open to both doctors and patients to get involved and can register their interest through either Patient or Doctor tab on the bottom of the page found here

Interested doctors, clinics or researchers can find out more about CMOS and register their interest here



CACOS – Epilepsy: currently recruiting

The Cannabis Access Clinics Observational Study: Observation of safety and health-related outcomes in patients with epilepsy undergoing medicinal cannabis therapy (CACOS-Epilepsy) has been ethics approved by Bellberry HREC Protocol No.2019-06-502.

This study will monitor several safety and health-related measures of patients engaged in medicinal cannabis treatment at Cannabis Access Clinics. This will help gain a better understanding of the role of medicinal cannabis in treating various health conditions including epilepsy and help shape future clinical trials.

This observational study follows people with epilepsy using the usual services of Cannabis Access Clinics, the only difference is patients may volunteer and consent to complete a number of surveys and have their data de-identified and included in the analysis to inform improvements in clinical care. As an observational study, there will be no changes to the type of medicine or dosages you are prescribed.

If you would like to participate or simply want more information please contact Cannabis Access Clinic study team on 1300 991 477 or email [email protected]

Expanding Medical Knowledge

Many people like to participate in research studies knowing that they are helping others by increasing the medical understanding of epilepsy, how seizures are treated and its impact on the lives of those affected by epilepsy.

In Australia there are strict rules governing human and animal research activities. Approval through a recognised ethics committee is needed to ensure there is minimal risk to the participant and potential benefit to the community from the findings.

Before you commit to participating in a clinical trial, it is best to be fully informed about the objectives of the research, what is expected of you and any risks and possible inconveniences that may be experienced during and after the trial.

There are many different types of clinical research studies that may or may not be of direct benefit to you and these include: